Purpose: To evaluate treatment outcomes and prognostic factors of pediatric
Introduction
Medulloblastoma (MB) is a disease that predominantly occurs in infants and children, and is the most-common type of pediatric malignant brain tumor, accounting for about 20% of all childhood brain cancers [1] .
In the pathology registry of the National Cancer Institute (NCI) Egypt, it constitutes 13.4% among all CNS tumors, the second most common tumor following malignant glioma (56%) [2] .
MB is a type of childhood primitive neuro ectodermal tumors (PNET). The incidence appears to occur in two peaks; the first peak is between 5 -9 years and the second peak is between 20 -30 years. The cell of origin is controversial, but probably it originates from germ native neuro-epithelial cells in the roof of the fourth ventricle. The typical location of MB is in the cerebellum (posterior vermis) (94%) and may encroach on the fourth ventricle. It commonly disseminates through the subarachnoid space through cerebrospinal fluid (CSF).
MB often presents with manifestations of increased intracranial pressure (headache and morning vomiting) due to obstructive hydrocephalus, which result from compression of the fourth ventricle. Seventy to 90% of patients with MB present with a history of headache, emesis, and lethargy, these symptoms are generally intermittent and subtle.
MB patients require full staging of the neural axis, including contrast-enhanced magnetic resonance imaging (MRI) of the brain and full spine and CSF cytological examination, due to high incidence of CSF dissemination.
At present, pediatric MB is divided into two risk groups: Average-risk patients: are those diagnosed when they are older than the age of 3 years with no metastases (M0) and totally or near-totally resected disease (<1.5 cm residual) on postoperative MRI or CT scan; or high-risk patients not fulfilling the criteria mentioned above [3] .
There are many pediatric MB treatment protocols however gross total resection followed by risk adaptive CSI (23.4 -36 Gy to whole neural axis followed by primary tumor site boost up to 54 -55.8 Gy) is the current treatment standard in pediatric patients who are over 3 years old.
Chemotherapy as part of the initial treatment was used to be reserved for patients with disseminated disease. However it is currently incorporated into regimens of all patients as it allows for reduction of CSI dose and its subsequent long term side effects.
The survival rate for pediatric patients with MB has increased significantly following improvements in imaging modalities, surgical techniques, risk adaptive CSI and the incorporation of active chemotherapeutic regimens. The use of these modalities in modern therapeutic protocols has resulted in a cure rate of approximately 70% -75% among children aged ≥3 years [4] [5].
This study aimed at evaluating the treatment outcome and prognostic factors for pediatric MB patients treated at the NCI, Cairo University, Egypt.
Patients and Methods
This is a retrospective study that included pediatric patients with pathologic diagnosis of MB treated at the RT Department, NCI, Cairo University from January 2006 to December 2013. The study received approval from ethical committee of NCI. Patients above the age of 18 years were excluded.
Data Collection
Data were collected and written in a data collection sheet. Data sheet included the following information:
Patients' related data (name, hospital number, phone number, RT number, date of birth geographical region of residence, date and age at diagnosis, Gender, family history, presenting symptoms, performance status, and neurological deficit at presentation).
Tumor related data including (histopathological grade, initial imaging studies of the brain and spine, CSF dissemination, size of residual after surgery, and risk stratification).
Treatment related data (initial use of ventriculo-peritoneal (VP) shunt, extent of surgery, use and sequencing of RT and CT; RT doses to the whole brain and the neural axis, total PF dose, response to treatment and additional use of surgery, RT and/or CT in case of relapse).
Outcome data including, OS and DFS measured from the date of pathologic diagnosis. Failures at the primary site PF, the brain, the spine, the meninges (widespread leptomeningeal disease) and/or at extra neural sites (primarily bone) were recorded as the only site of first failure or as a component of first failure. Failure included recurrence or progression of initial disease or relapse in a site free of disease at presentation. The time of failure was determined as the date at which radiologic or biopsy confirmation of relapse at one of these sites occurred.
Statistical Analysis
Data were analyzed using SPSS win statistical package version 21. Numerical data were expressed as mean and standard deviation (SD), median and range as appropriate. Qualitative data were expressed as frequency and percentage. Chisquare (Fisher's exact) test was used to examine the relation between qualitative variables as appropriate. Logistic regression model was done to predict effect of different independent factors on patient response to treatment through calculating odds ratio and its 95% confidence interval (CI). Survival analysis was done using Kapler-Meier method with log rank test for comparison. Multivariate analysis was done by Cox regression model to test for independent prognostic effect of statistically significant variables on univariate level with calculating hazard ratio and its 95% CI. Correction of P value was done using Benferroni adjustment to avoid hyperinflation of type 1 error resulting from multiple comparisons. P value ≤ 0.05 was considered significant and all tests were 2 tailed. OS was calculated from date of accurate diagnosis till date of death or last follow up.
PFS was calculated from date of start of treatment (date of surgery) till date of relapse, death or last follow up.
Results
Between 2006 and 2013, the records of 50 pediatric MB patients were analyzed.
Median age was 6 years (range 3 -18 years), 29 males and 21 females. The cardinal symptom at presentation was vomiting (74%), followed by headache (64%). Other symptoms as blurring of vision, cranial nerve affection, and gait disturbance occurred with less percentages. According to the Chang staging system; 38%, 44%, 4%, and 14% were M0, M1, M2, and M3, respectively, CSF dissemination was found in 60%. High risk patients (>1.5 cm 2 residual, or M+) comprised 78% (39/50) of the studied patients compared to 22% (11/50) standard risk patients (≤1.5 cm 2 residual, and M0). Median tumor size was 4.5 cm, ranging from 2 to 9 cm (Table 1) .
Surgery
All 50 patients underwent an attempt for total resection to the extent compatible or otherwise considered as a biopsy 20% (10/50) ( Table 1) .
Radiation Therapy (RT)
All patients received adjuvant RT according to risk stratification. High risk pa- Usually, the cranial field length was decreased by 2 cm each 10 Gy with subsequent increase in the upper spinal field length with no shift of the iso-center. If there were two spinal fields, the lower field length was decreased keeping the corresponding skin gap. It is therefore possible for the thyroid gland to get exit dose from the spine field with a new junction change, even if the original spinal field did not exit or diverge into the thyroid gland. Patients were treated using a 6-MV linear accelerator.
Chemotherapy
All patients received CT; concurrent with RT (vincritine) (94%) and adjuvant CT (100%), whereas, 4 patients (8%) only received neoadjuvant CT (i.e. before RT). (NB: only one patient received neoadjuvant, concomitant, and adjuvant CT).
Response to Treatment
Assessment was done 6 months after adjuvant CT. In 92% of cases there was tumor response 60% CR and 32% PR (Table 1) .
Only geographical region, gender, performance status, extent of surgery, and postoperative residual showed statistically significant correlation with response to treatment on univariate analysis (Table 2) On multivariate analysis only post-operative residual tumor was significantly correlated with response to treatment statistically with 25 times higher risk (OR 24.9, 95% CI 2.9 -46.9, P value 0.003).
Survival and Patterns of Relapse
With a median follow-up of 32.5 (range 6 -104) months, four patients relapsed after treatment. One patient had distant relapse, and was treated with RT. Two patients had local relapse, both were treated with palliative CT, and one of them received palliative RT in addition. One patient had both local & spinal relapses, and was treated with palliative CT. Seventeen patients died of their disease (Table 3) . 
Overall Survival
For the whole group, the surviving proportion estimates at 1, 3, and 5 years were 83%, 70%, and 64%, respectively. In the univariate analysis, geographical region (P = 0.016), performance status (P = 0.026), extent of surgery (P = 0.010), and post-operative residual tumor size (P = 0.015) were significant prognostic factors for OS (Table 4 , Figures 1-3) , while other factors were not statistically significant. 
Progression Free Survival (PFS)
In the univariate analysis, gender (P = 0.032), extent of surgery (P = 0.036), and post-operative residual tumor size (P = 0.013) were significantly correlated with PFS statistically (Table 5 , Figures 4-6) , while other factors were not statistically significant.
On multivariate analysis only gender and presence of post-operative residual tumor, were statistically significant by Cox-Regression hazard model. Hazard ratio was 3.6 with 95% CI 1.2 -11 and p value 0.024 for gender and 3.5 with 95%
CI 1 -12 and P value 0.049 for post op residual.
Discussion
The standard of care for pediatric patients with MB includes; a combination of maximal safe resection, risk adaptive CSI followed by boost to PF, and adjuvant CT. Patients who undergo a gross total or subtotal resection for non-metastatic Figure 3 . OS analysis according to type of surgery. MB have a better outcome than those who have a biopsy alone followed by RT, with reported five-year survival of (69% -89% versus 27% -43%) for patients with gross total or subtotal resection compared to biopsy alone [6] [7].
Demographic Data
In this study, 29 out of 50 patients were males (58%) 1.38:1. This is consistent with national and international studies reporting a slight male predominance [8] [9]. In similar national studies, males constituted (57%) in previous NCI study [10] , and (51.4%) in a larger Kasr Al Aini study [11] . In a meta-analysis of 10,582 childhood brain tumors, male to female ratio was reported to be 1.29:1 [12] . On the other hand, other studies reported a slight female predominance [13] [14].
Clinical Data
In this study, vomiting was the most frequent presentation followed by headache, 74% and 64%, respectively. Findings are consistent with Kasr Al-Aini study, (77.4% and 75.6%, respectively) [11] and an international meta-analysis of 4171 children with intracranial tumors (75%, and 67% respectively) [15] .
As regards M stage, M0/M1 patients in this series had a higher 5-year PFS 
Treatment Data
Standard therapy includes maximal safe resection of the tumor, RT to the entire craniospinal axis with boost to PF (for patients >3 years), followed by adjuvant Adjuvant CT has been shown to improve outcome in children with MB. The efficacy of CT in the treatment of MB has been assessed previously in two large randomized trials conducted by the International Society of Pediatric Oncology [20] . The addition of CT for high-risk patients seems to improve their survival and has led to better outcome even in average-risk patients. In this study, all patients were treated with CT; CCRT (94%), adjuvant CT (100%), while only 8%
were treated with neoadjuvant CT (i.e. before RT) compared with only 67% in earlier national studies [10] . This may be explained by the recent increased role of CT in treatment of MB patients, and its inclusion as a standard of care in in- 
Survival
In this study, the OS rates at 3 and 5 years were 70% and 64%, respectively. The latter is comparable to other studies where it ranged from 60% [26] Gender is a controversial prognostic factor in pediatric series. In this study, female gender had significant favorable impact on PFS which is comparable to other studies [34] [35] [36] .
Prognostic Factors
In this study, the interval between surgery and the start of RT did not show influence on survival. Results are comparable to previous national study [10] .
Certain studies have shown a correlation between completion of RT in the prescribed OTT and improved PF control [36] while other studies did not prove that correlation [10] [20] . In this study, OTT did not show significance for better outcome (P = 0.194). Interesting to note is that the OTT at NCI has increased from a reported median of 45 days (during the period from 1997 to 2004) to 52 days in this study (during the period from 2006 to 2013) and that did not lead to poorer results.
Conclusions
Neural-axis relapse is the most common site of relapse for pediatric MB patients.
Extent of surgical resection, post-operative residual tumor, and gender were powerful prognostic factors. Maximal safe resection is the standard surgical approach for MB patients to achieve cure.
The role of interval between surgery and the start of RT and adjuvant highdose CT especially for high-risk pediatric MB patients require further investigation. Late recurrences are not rare; therefore, long-term follow-up is needed.
Pediatric neurosurgery is a subspecialty that needs further advanced training programs to be able to follow the rapid-pace advancements in this field. In the same way, departments/centers of pediatric oncology need to be established and developed in Nile Delta cities to help for early detection and proper management of pediatric cancer patients in this region. The absence of this specialty in the cancer centers of Nile Delta leads to mismanagement of those patients, which leads to their presentation to NCI with advanced stage to the extent that it significantly affected the OS in this study.
